ACT Signature Webinar series provides accessible education to members of the toxicology community worldwide. The Signature Webinars are held on a quarterly basis and are free to both ACT members and nonmembers for live and on-demand viewing.
These educational webinars cover current topics in toxicology and are presented by experts in the field, with backgrounds in government, industry, or academia. Each Signature Webinar is approximately 90 minutes, which includes a 30-minute questions and answers session with the speaker(s) following the presentation.
After each live event a recording of the presentation is placed in the ACT Signature Webinar Archives.
Upcoming Webinar
The Complement Cascade—When Activation Mediates Toxicity
May 3, 2023 at 11:30 AM–1:00 PM Eastern
Hosted by the American College of Toxicology
With support from: The British Toxicology Society and the Society of Toxicologic Pathology
Speaker:
Ashley Frazer-Abel, PhD, Exsera BioLabs at University of Colorado Medicine
There is no fee, but advance registration is required.
Webinar Archives
- An Overview of Nonclinical Considerations in Translating AAV Gene Therapies to the Clinic
- Assessing the Environmental Risk of Pharmaceuticals following Patient Use
- Computational Toxicology: A Useful Tool for Hazard Identification and Risk Assessment?
- Defining the INDefinable: US FDA Regulatory Applications
- Fundamental Approaches to Immunotoxicity Assessment in Preclinical Safety Studies
- History and Risk Assessment of Vaccines: A Practical Perspective from an Immunologist and a Toxicologist
- Impurities: The Good, the Bad, and the Ugly
- Juvenile Animal Studies: Regulatory and Industry Perspectives
- Nonclinical Abuse Liability Testing of Biologics
- Preclinical Considerations for Cell-Based Immunotherapies
- Reproduction, Development, and Pathology: Finding Common Ground
- Safety Assessment of Metabolites in Drug Development: Current Perspective
- Safety Testing of Metabolites
- Talking Tox When Others Don’t “Speak the Language”
- The Veterinary Pathologist’s Role in the 3Rs
- Understanding Developmental and Reproductive Toxicity Studies
- Adversity in Nonclinical Reporting: Myths, Legends, and Reality
- Approach to Development of an Inhalation Excipient for Regulatory Approval: Case Studies with HFA-152a and DSPC
- Impurities Safety Evaluation
- Influence of the Microbiota in Drug Development and Preclinical Studies
- Nonclinical Safety Assessment of Prophylactic and Therapeutic Vaccines
- Preclinical Medical Device Safety Evaluation in 2022
- Preparing for Regulatory Interactions: How Much Is Enough?
- Safety Assessment of Monoclonal Antibodies for Immunosuppressants and Anti-Inflammatory Agents
- A Regulatory and Industry Perspective on the Introduction and Application of GLP Regulations: What They Are, Why They Matter, and How They Apply to Toxicology Studies
- Adversity in Nonclinical Reporting: Myths, Legends, and Reality
- Best Practices of Communication: How to Communicate with Your CRO and/or Client
- Carcinogenicity Assessment of Biologics
- Early Toxicology Studies—From Design to Dose Selection: What You Need to Know
- Immunological Assessments of Viral Vectors Expressing Multiple Cytokine Transgenes in Nonclinical Studies
- Implications for Tox/TK When ISR Fails
- Mini-Pig Use in Safety Assessments during Drug Development
- Pathology Peer Review and the OECD Guidance on the GLP Requirements: A Review of the Review
- Preparing for Nonclinical eData Regulatory Submissions to the US FDA—“SEND” and Beyond
- Regulatory and Scientific Challenges in Biosimilar Development: Nonclinical Considerations
- An Overview of Nonclinical Considerations in Translating AAV Gene Therapies to the Clinic
- Animal Models of Disease for Nonclinical Safety Assessment: Pharmaceutical Industry Survey
- Applications of iPS-Cell Derived Tissues in Safety Assessment
- Approach to Development of an Inhalation Excipient for Regulatory Approval: Case Studies with HFA-152a and DSPC
- Mechanistic Approaches Using 3D Microtissues to Evaluate Preclinical and Clinical Drug-Induced Liver Injury
- Practical Nanotoxicology
- Understanding Your Model: Considerations for Use of Tg.rasH2 Mice in Carcinogenicity Assessmenty